Literature DB >> 20347784

Hypertrophic cardiomyopathy.

Carolyn Y Ho1.   

Abstract

Important insights into the molecular basis of hypertrophic cardiomyopathy and related diseases have been gained by studying families with inherited cardiac hypertrophy. Integrated clinical and genetic investigations have demonstrated that different genetic defects can give rise to the common phenotype of cardiac hypertrophy. Diverse pathways have been identified, implicating perturbations in force generation, force transmission, intracellular calcium homeostasis, myocardial energetics, and cardiac metabolism in causing disease. Although not fully elucidated, the fundamental mechanisms linking gene mutations to clinical disease are being characterized. Further advances will allow a better understanding of pathogenesis, diagnosis, and treatment, not just of relatively rare inherited cardiomyopathies, but potentially also of relevance to more common acquired forms of hypertrophic remodeling. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20347784      PMCID: PMC3031113          DOI: 10.1016/j.hfc.2009.12.001

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  76 in total

1.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

2.  The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation.

Authors:  D Georgakopoulos; M E Christe; M Giewat; C M Seidman; J G Seidman; D A Kass
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

3.  Sudden death due to troponin T mutations.

Authors:  J C Moolman; V A Corfield; B Posen; K Ngumbela; C Seidman; P A Brink; H Watkins
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

4.  Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  M Spindler; K W Saupe; M E Christe; H L Sweeney; C E Seidman; J G Seidman; J S Ingwall
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy.

Authors:  Michael Arad; Barry J Maron; Joshua M Gorham; Walter H Johnson; J Philip Saul; Antonio R Perez-Atayde; Paolo Spirito; Gregory B Wright; Ronald J Kanter; Christine E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

Review 6.  The genetic basis for cardiac remodeling.

Authors:  Ferhaan Ahmad; J G Seidman; Christine E Seidman
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

Review 7.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; J G Seidman; Christine E Seidman
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

8.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

9.  Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  E Blanchard; C Seidman; J G Seidman; M LeWinter; D Maughan
Journal:  Circ Res       Date:  1999-03-05       Impact factor: 17.367

10.  A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy.

Authors:  A Freiburg; M Gautel
Journal:  Eur J Biochem       Date:  1996-01-15
View more
  20 in total

Review 1.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

2.  Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults.

Authors:  Sara B Seidelmann; Emily Smith; Lakshman Subrahmanyan; Daniel Dykas; Maen D Abou Ziki; Bani Azari; Fady Hannah-Shmouni; Yuexin Jiang; Joseph G Akar; Mark Marieb; Daniel Jacoby; Allen E Bale; Richard P Lifton; Arya Mani
Journal:  Circ Cardiovasc Genet       Date:  2017-02

Review 3.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.

Authors:  Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2017-08-24       Impact factor: 5.460

4.  Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.

Authors:  Chen-Ching Yuan; Priya Muthu; Katarzyna Kazmierczak; Jingsheng Liang; Wenrui Huang; Thomas C Irving; Rosemeire M Kanashiro-Takeuchi; Joshua M Hare; Danuta Szczesna-Cordary
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 5.  Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.

Authors:  Maksymilian Prondzynski; Giulia Mearini; Lucie Carrier
Journal:  Pflugers Arch       Date:  2018-07-03       Impact factor: 3.657

Review 6.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

Review 7.  Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.

Authors:  Hamayak Sisakian
Journal:  World J Cardiol       Date:  2014-06-26

8.  Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM.

Authors:  Sunil Yadav; Chen-Ching Yuan; Katarzyna Kazmierczak; Jingsheng Liang; Wenrui Huang; Lauro M Takeuchi; Rosemeire M Kanashiro-Takeuchi; Danuta Szczesna-Cordary
Journal:  J Mol Med (Berl)       Date:  2019-05-17       Impact factor: 4.599

9.  Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.

Authors:  Polina Sysa-Shah; Yi Xu; Xin Guo; Frances Belmonte; Byunghak Kang; Djahida Bedja; Scott Pin; Noriko Tsuchiya; Kathleen Gabrielson
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

10.  Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics.

Authors:  Polakit Teekakirikul; Robert F Padera; J G Seidman; Christine E Seidman
Journal:  J Cell Biol       Date:  2012-10-29       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.